Dose selection of adjuvanted synthetic nanocarriers
Disclosed are synthetic nanocarrier compositions with coupled adjuvant compositions as well as related methods.
1. A method for increasing local immune cytokine induction but not systemic induction of pro-inflammatory cytokines comprising:
generating a systemic cytokine release through administration to a subject of a dose of an adjuvant, wherein at least a portion of the dose of the adjuvant is coupled to synthetic nanocarriers and
choosing the dose of the coupled adjuvant to be greater than a separate dose of the adjuvant which is not coupled to synthetic nanocarriers, wherein the administration of the coupled adjuvant results in a systemic cytokine release similar to that generated through administration of the dose of the not-coupled adjuvant to the subject.
2. The method of claim 1 , wherein the method further comprises providing the dose of adjuvant.
3. The method of claim 1 or 2 , wherein the adjuvant comprises an agonist for Toll-Like Receptors 3, 4, 5, 7, 8, or 9 or a combination thereof.
4. The method of claim 1 or 2 , wherein the dose of adjuvant comprises two or more types of adjuvants.
5. The method of claim 1 or 2 , wherein the method further comprises administering more than one type of antigen to the subject.
6. The method of claim 5 , wherein at least a portion of the dose of antigen(s) is coupled to the synthetic nanocarriers.
7. The method of claim 5 , wherein the antigen(s) comprise a B cell antigen or a T cell antigen or both.
8. The method of claim 1 or 2 , wherein the synthetic nanocarriers comprise lipid nanoparticles, polymeric nanoparticles, metallic nanoparticles, surfactant-based emulsions, dendrimers, buckyballs, nanowires, virus-like particles, peptide or protein particles, nanoparticles that comprise a combination of nanomaterials, spheroidal nanoparticles, cuboidal nanoparticles, pyramidal nanoparticles, oblong nanoparticles, cylindrical nanoparticles, or toroidal nanoparticles.
9. The method of claim 1 or 2 , wherein the synthetic nanocarriers comprise one or more polymers.
10. The method of claim 1 or 2 , wherein at least one dosage form comprises the dose of adjuvant.
11. The method of claim 1 or 2 , wherein the subject has cancer, an infectious disease, a non-autoimmune metabolic disease, a degenerative disease, an addiction, and atopic condition, asthma, chronic obstructive pulmonary disease (COPD) or a chronic infection.